Post-ERCP Pancreatitis: Prevention, Diagnosis and Management
Por:
Cahyadi, O, Tehami, N, De-Madaria, E and Siau, K
Publicada:
1 sep 2022
Ahead of Print:
12 sep 2022
Resumen:
Endoscopic retrograde cholangiopancreatography (ERCP) carries a post-ERCP pancreatitis (PEP) rate of 2-10%, which could be as high as 30-50% in high-risk cases. PEP is severe in up to 5% of cases, with potential for life-threatening complications, including multi-organ failure, peripancreatic fluid collections, and death in up to 1% of cases. The risk of PEP is potentially predictable and may be modified with pharmacological measures and endoscopist technique. This review covers the definition, epidemiology and risk factors for PEP, with a focus on the latest evidence-based medical and endoscopic strategies to prevent and manage PEP.
Filiaciones:
Cahyadi, O:
Hosp Ruhr Univ Bochum, St Josef Hosp, D-44791 Bochum, Germany
Tehami, N:
Univ Hosp Southampton NHS Fdn Trust, Dept Gastroenterol, Southampton SO16 6YD, Hants, England
:
Miguel Hernandez Univ, Dept Gastroenterol, Dr Balmis Gen Univ Hosp, Alicante 03010, Spain
Miguel Hernandez Univ, Dept Clin Med, Alicante 03010, Spain
Alicante Inst Hlth & Biomed Res ISABIAL, Alicante 03010, Spain
Siau, K:
Royal Cornwall Hosp NHS Trust, Dept Gastroenterol, Truro TR1 3LJ, England
Univ Birmingham, Med & Dent Sci, Birmingham B4 6BN, W Midlands, England
gold, Green Published
|